—
C+
C+ The full Closelook — membership. Open the C+ overview

Curaleaf Holdings Inc. (CURA.TO) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Curaleaf Holdings Inc.

CURA.TO in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Curaleaf grows, processes and sells cannabis products for both medical and recreational use, running licensed cultivation and manufacturing sites across the United States. It also supplies wholesale cannabis to markets in Australia, New Zealand, the United Kingdom and several European countries, and runs a medical cannabis clinic alongside a pharmacy licence. It is based in Stamford, Connecticut.
Where it sits in the stack
Curaleaf sits outside our AI build-out index; the diary tracks it within the wider healthcare and specialty-drug sleeve of our universe as a cannabis cultivation and retail name.
Who it is priced against
The diary has no set peer group for this name; the comparison the market most often draws is with Tilray, another vertically integrated cannabis operator.
Why Closelook tracks it
Curaleaf holds no seat in our index, carries no Closelook score yet, and has not appeared in any edition or quote so far.
What the diary watches
Whether Curaleaf's wholesale expansion into new European markets changes the balance between its US retail business and international supply.

Curaleaf Holdings Inc. (CURA.TO) trades on the TO exchange in Canada, classified under Healthcare.

The Closelook company score reads 31/100 composite (momentum 65, quality 22, valuation 26) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for CURA.TO, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - Specialty & Generic · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against CURA.TO on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months · buybacks 256,000 CAD in FY2025

Dividends and capital return

What CURA.TO pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 256,000 CAD 0.0% of today's market value
  • Share count +2.6% in FY2025 36 m CAD of stock-based compensation in the year
  • Capital returned 256,000 CAD · 0% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Curaleaf Holdings Inc. (CURA.TO)?

Curaleaf Holdings Inc. trades as CURA.TO on the TO exchange (Canada) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is CURA.TO in a Closelook index?

Not currently — Curaleaf Holdings Inc. is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is Curaleaf Holdings Inc.'s Closelook composite score?

31 out of 100, with momentum 65, quality 22 and valuation 26 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

What does Curaleaf Holdings Inc. do?

Curaleaf grows, processes and sells cannabis products for both medical and recreational use, running licensed cultivation and manufacturing sites across the United States. It also supplies wholesale cannabis to markets in Australia, New Zealand, the United Kingdom and several European countries, and runs a medical cannabis clinic alongside a pharmacy licence. It is based in Stamford, Connecticut. The diary has no set peer group for this name; the comparison the market most often draws is with Tilray, another vertically integrated cannabis operator.

Where does Curaleaf Holdings Inc. sit in the AI build-out?

Curaleaf sits outside our AI build-out index; the diary tracks it within the wider healthcare and specialty-drug sleeve of our universe as a cannabis cultivation and retail name. Curaleaf holds no seat in our index, carries no Closelook score yet, and has not appeared in any edition or quote so far.

Does Curaleaf Holdings Inc. pay a dividend?

No cash distribution shows in Curaleaf Holdings Inc.’s price series over the last three years. In fiscal 2025 the company bought back 256,000 CAD of its own shares, 0% of that year’s free cash flow. The share count rose 2.6% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for CURA.TO, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.